Young Women's Breast Cancer Awareness and Survivorship Needs in Underserved Communities
Protocol #: 21-3898
Locations: Cherry Creek Medical Center; Lone Tree Medical Center; University of Colorado Hospital
|
An Open-Label, Multicenter, Phase 1a Study of AN2025 and AN0025 in Double Combination with Atezolizumab and in Triple Combination with Atezolizumab in Patients with Advanced Solid Tumors
Protocol #: 21-4026
Location: University of Colorado Hospital
|
Decision making for urinary diversion in patients with bladder cancer
Protocol #: 21-3661
Location: University of Colorado Hospital
|
An Open-label, Fixed-sequence Study to Assess the Effect of Repeated Doses of Capivasertib on the Pharmacokinetics of Oral Midazolam (a CYP450 3A Probe) in Patients With Advanced Solid Tumours Harbouring Alterations in the PI3K/AKT/PTEN Pathway
Protocol #: 21-3737
Location: University of Colorado Hospital
|
Phase I/II trial of radiotherapy in combination with Atezolizumab prior to surgical resection for HPV-unrelated squamous cell carcinoma of the head and neck (HNSCC)
Protocol #: 21-2642
Locations: Highlands Ranch Hospital; Memorial Hospital Central; Memorial Hospital North; University of Colorado Hospital
|
Advanced Planning for Online Accounts and Data
Protocol #: 21-3375
Location: University of Colorado Hospital
|
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations
Protocol #: 21-3431
Location: University of Colorado Hospital
|
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D
Protocol #: 21-3366
Location: University of Colorado Hospital
|
A071702 A PHASE II STUDY OF CHECKPOINT BLOCKADE IMMUNOTHERAPY IN PATIENTS WITH SOMATICALLY HYPERMUTATED RECURRENT GLIOBLASTOMA
Protocol #: 21-3021
Location: University of Colorado Hospital
|
A091902 - A MULTICENTER PHASE II TRIAL OF PACLITAXEL WITH AND WITHOUT NIVOLUMAB IN TAXANE NAIVE, AND NIVOLUMAB AND CABOZANTINIB IN TAXANE PRETREATED SUBJECTS WITH ANGIOSARCOMA
Protocol #: 20-3096
Location: University of Colorado Hospital
|
S2000 - A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases
Protocol #: 21-2584
Location: University of Colorado Hospital
|
A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients with Solid Tumors
Protocol #: 21-3286
Location: University of Colorado Hospital
|
Observational Protocol: Trametinib therapy for Symptomatic Patients with RAS/MAPK-Pathway Mutation-Positive Disorders
Protocol #: 21-3183
Location: Childrens Hospital Colorado
|
A MULTICENTER PROSPECTIVE STUDY EVALUATING OUTCOMES OF ENDOSCOPIC ERADICATION THERAPY IN PATIENTS WITH BARRETT'S ESOPHAGUS ASSOCIATED NEOPLASIA: THE TREAT-BE (TREATMENT WITH RESECTION AND ENDOSCOPIC ABLATION TECHNIQUES FOR BARRETT'S ESOPHAGUS) CONSORTIUM
Protocol #: 14-2371
Locations: Moffit Cancer Center, University of South Florida; Northwestern University; UCLA - University of California; University of Colorado Hospital; University of Kansas Cancer Center; Washington University, Siteman Cancer Center
|
First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors
Protocol #: 21-3039
Location: University of Colorado Hospital
|
The effects of cardiorespiratory fitness, physical activity and sedentary behavior on insulin resistance among breast cancer survivors being treated with anti-estrogen endocrine therapies.
Protocol #: 21-3245
Locations: Anschutz Health and Wellness; Outpatient CTRC; University of Colorado Hospital
|
A Phase 1 Study of RTX-321 for the Treatment of Patients with Advanced Malignancies Associated with Human Papillomavirus-16 Infection
Protocol #: 21-3219
Locations: Outpatient CTRC; University of Colorado Hospital
|
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Anti-PD-1 in Patients with Metastatic Solid Tumors
Protocol #: 20-2976
Location: University of Colorado Hospital
|
A Phase Ib/III Randomised Study of Capivasertib plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and
Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Protocol #: 21-3077
Location: University of Colorado Hospital
|
A Randomized Phase II Trial of Cabozantinib Combined with PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
Protocol #: 21-2726
Location: University of Colorado Hospital
|
A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined with Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small Cell Lung Cancer (NSCLC)
Protocol #: 20-2832
Location: University of Colorado Hospital
|
PEPN1924: A PHASE 2 STUDY OF DS-8201A (NSC# 807708, IND# TBD) IN ADOLESCENTS, OR YOUNG ADULTS WITH RECURRENT HER2+ OSTEOSARCOMA
Protocol #: 21-2749
Location: Childrens Hospital Colorado
|
A PHASE 2, MULTICENTER, RANDOMIZED STUDY OF TRASTUZUMAB ERUXTECAN IN HER2-MUTATED METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) [DESTINY-LUNG02]
Protocol #: 21-2686
Locations: Outpatient CTRC; University of Colorado Hospital
|
A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis
Protocol #: 20-3032
Locations: Outpatient CTRC; University of Colorado Hospital
|
A PHASE 1 OPEN-LABEL STUDY OF KPT-9274 IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA
Protocol #: 20-2350
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on a PD-1 Inhibitor
Protocol #: 21-2670
Locations: Outpatient CTRC; University of Colorado Hospital
|
A011801 - The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Protocol #: 21-2558
Locations: Greeley Campus; Harmony Campus; Highlands Ranch Hospital; Lone Tree Medical Center; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital
|
A randomized registry trial of adjuvant mitotane vs. mitotane with cisplatin/etoposide after primary surgical resection of localized adrenocortical carcinoma with high risk of recurrence (ADIUVO-2 Trial)
Protocol #: 20-2214
Location: University of Colorado Hospital
|
Neurocognitive Function in the Pediatric Hematology Oncology Population
Protocol #: 20-2765
Location: Childrens Hospital Colorado
|
A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus) (ADDRESS)
Protocol #: 20-2721
Locations: Outpatient CTRC; University of Colorado Hospital
|
A RANDOMIZED, PHASE II TRIAL OF CIRCULATING TUMOR DNA-GUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK, STAGE II-III, ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER (DARE)
Protocol #: 20-2773
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Protocol #: 20-2818
Location: University of Colorado Hospital
|
APEC1621I: NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF PALBOCICLIB IN PATIENTS WITH TUMORS HARBORING ACTIVATING ALTERATIONS IN CELL CYCLE GENES
Protocol #: 17-2168I
Location: Childrens Hospital Colorado
|
A Phase I-II multicenter, open label trial of H3B-6545, a covalent antagonist of estrogen receptor alpha, in women with locally advanced or metastatic estrogen receptor-positive, HER2 negative breast cancer
Protocol #: 20-2675
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
A PHASE 2, MULTI-COHORT, OPEN-LABEL STUDY OF INTRATUMORAL TAVOKINOGENE TELSEPLASMID PLUS ELECTROPORATION IN COMBINATION WITH INTRAVENOUS PEMBROLIZUMAB THERAPY WITH OR WITHOUT CHEMOTHERAPY IN PATIENTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER.
Protocol #: 20-2737
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
Physician Selected Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
Protocol #: 20-2202
Location: University of Colorado Hospital
|
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1
Protocol #: 20-2697
Location: University of Colorado Hospital
|
A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination with Cetuximab in Participants with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated with an Immune Checkpoint Inhibitor
Protocol #: 20-2644
Location: Rocky Mountain Regional VA Medical Center
|
Intermediate-size Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas
Protocol #: 20-2681
Location: Childrens Hospital Colorado
|
A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined with Anti-Cancer
Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small
Cell Lung Cancer (NSCLC)
Protocol #: 20-6512
Locations: Memorial Hospital Central; Memorial Hospital North
|
A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients with Advanced Solid Tumors
This is a Phase I/II trial with at least 17 patients in the dose escalation phase
and 26-45 patients in the Phase II portion of the trial. In the Phase I portion of
the trial, patients will receive EMB-02 at doses escalating from 6 to 900 mg IV
once weekly. Following the evaluation of i...more >
Protocol #: 20-2545
Locations: Memorial Hospital Central; Memorial Hospital North
|
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Cisplatin-Ineligible Participants with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)
Protocol #: 20-2607
Locations: Highlands Ranch Hospital; University of Colorado Hospital
|
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies
Protocol #: 20-2584
Location: University of Colorado Hospital
|
S1823 - A PROSPECTIVE OBSERVATIONAL COHORT STUDY TO ASSESS miRNA 371 FOR OUTCOME PREDICTION IN PATIENTS WITH NEWLY DIAGNOSED GERM CELL TUMORS
Protocol #: 20-2392
Locations: Greeley Campus; Harmony Campus; Highlands Ranch Hospital; Medical Center of the Rockies; Poudre Valley Hospital; University of Colorado Hospital
|
A PHASE 1 STUDY OF TJ210001 ADMINISTERED IN SUBJECTS WITH RELAPSED OR REFRACTORY ADVANCED SOLID TUMORS
Protocol #: 20-2541
Location: University of Colorado Hospital
|
Biomarker Development for Sepsis in Pediatric Oncology Patients
Protocol #: 20-2374
Location: Childrens Hospital Colorado
|
A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment
Protocol #: 20-2383
Location: University of Colorado Hospital
|
A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Protocol #: 20-1994
Location: University of Colorado Hospital
|
Paired Germline/Tumor Genetic Testing Outcomes
Protocol #: 20-2287
Locations: Childrens Hospital Colorado; Childrens Hospital Colorado at Memorial
|
EF-32 (TRIDENT): A PIVOTAL RANDOMIZED, OPEN-LABEL STUDY OF OPTUNE? (TTFIELDS, 200KHZ) CONCOMITANT WITH RADIATION THERAPY AND TEMOZOLOMIDE FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA
Protocol #: 20-2112
Location: University of Colorado Hospital
|
A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects with Advanced and/or Metastatic Hormone Receptor (HR)-positive, HER2-negative Breast Cancer
Protocol #: 20-2279
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
AREN1921 - Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Protocol #: 20-2414
Location: Childrens Hospital Colorado
|
NRG-LU007: Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Protocol #: 20-2369
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital
|
ARST1921 - A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
Protocol #: 20-2411
Location: Childrens Hospital Colorado
|
A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma
Protocol #: 20-2294
Location: Rocky Mountain Regional VA Medical Center
|
S1929: Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Protocol #: 20-2084
Locations: Greeley Campus; Harmony Campus; Lone Tree Medical Center; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital
|
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
Protocol #: 20-2167
Location: University of Colorado Hospital
|
Sexuality and breast cancer: Developing appropriate education for women going through treatment
Protocol #: 20-1789
Location: University of Colorado Hospital
|
A Phase 1 Study of SRF617 in Patients With Advanced Solid Tumors
Protocol #: 20-2199
Location: University of Colorado Hospital
|
S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab(NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Protocol #: 20-2083
Locations: Greeley Campus; Harmony Campus; Highlands Ranch Hospital; Lone Tree Medical Center; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital
|
A Phase 1 Study of FT-7051 in Men with Metastatic Castration-Resistant Prostate Cancer
Protocol #: 20-2228
Location: University of Colorado Hospital
|
Non-Operative Management and Early Response Assessment in Rectal Cancer (NOM-ERA)
Non-Operative Management and Early Response Assessment in Rectal Cancer (NOM-ERA)...more >
Protocol #: 20-2227
Locations: Memorial Hospital Central; Memorial Hospital North
|
EA2186: A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naive Metastatic Pancreatic Cancer (GIANT)
Protocol #: 20-2150
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital
|
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer
Protocol #: 20-2042
Locations: Outpatient CTRC; University of Colorado Hospital
|
An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies
Protocol #: 20-1948
Location: Rocky Mountain Regional VA Medical Center
|
A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX)
Protocol #: 20-1907
Location: University of Colorado Hospital
|
ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB, AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB, IN PATIENTS WITH ADVANCED OR METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA OR MYXOFIBROSARCOMA WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY
Protocol #: 20-1892
Location: University of Colorado Hospital
|
A Phase 1 Open Label, Multi-Center Study to Evaluate the Safety and Tolerability of BXQ-350 in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)
Protocol #: 20-1447
Location: Childrens Hospital Colorado
|
LUNGMAP: A MASTER PROTOCOL TO EVALUATE BIOMARKER-DRIVEN THERAPIES AND IMMUNOTHERAPIES IN PREVIOUSLY-TREATED NON-SMALL CELL LUNG CANCER (Lung-MAP Screening Study)
Protocol #: 20-1813
Location: Rocky Mountain Regional VA Medical Center
|
A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)
Protocol #: 20-1837
Location: University of Colorado Hospital
|
A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE-FINDING, PHARMACOKINETIC, SAFETY AND TOLERABILITY STUDY OF PF-07265807 IN PARTICIPANTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES
Protocol #: 20-1845
Location: University of Colorado Hospital
|
AN EXPANDED ACCESS, SINGLE-ARM, MULTICENTER STUDY TO PROVIDE AT HOME SUBCUTANEOUS ADMINISTRATION OF PERTUZUMAB AND TRASTUZUMAB FIXED-DOSE COMBINATION (PH FDC SC) FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER DURING THE COVID-19 PANDEMIC
Protocol #: 20-1830
Location: University of Colorado Hospital
|
A221805: Duloxetine To Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IITo Phase III Study
Protocol #: 20-1705
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital
|
S1714: A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane Induced Peripheral Neuropathy in Cancer Patients
Protocol #: 19-2216
Location: Rocky Mountain Regional VA Medical Center
|
S1827: MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Protocol #: 20-1704
Location: Rocky Mountain Regional VA Medical Center
|
Brigatinib Before Brain Irradiation Trial (B3i Trial): A Phase II Trial of Brigatinib Alone for Brain Metastases from ALK+ Lung Cancer
Protocol #: 19-2862
Locations: City of Hope Cancer Center; Mayo Clinic, Rochester; University of Colorado Hospital
|
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
Protocol #: 20-1667
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
A First-in-Human, Two-Part, Open-Label, Phase I/II Study of DSP107 in Subjects with Advanced Solid Tumors Including a Dose-Escalation Safety Study (Part 1) and Preliminary Efficacy Assessment of DSP107 as Monotherapy and in Combination with Atezolizumab (Part 2)
Part 1 of the study is open to all solid tumors. Part 2 of the study will evaluate the safety, tolerability and preliminary efficacy of
DSP107, administered either as monotherapy or in combination with atezolizumab.
The study will enrol subjects with NSCLC that is wildtype for actionable...more >
Protocol #: 20-1690
Location: University of Colorado Hospital
|
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Protocol #: 20-1555
Locations: Outpatient CTRC; University of Colorado Hospital
|
A Phase I study of the ADAM-10 inhibitor, INCB007839 in children with recurrent/progressive high-grade gliomas to target microenvironmental neuroligin-3
Protocol #: 20-1487
Location: Childrens Hospital Colorado
|
Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitor, as a Single Agent or with Irinotecan, Temozolomide/Irinotecan or Cyclophosphamide/Topotecan in Pediatric Patients with Refractory Malignancies
Protocol #: 20-1445
Location: Childrens Hospital Colorado
|
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302)
Protocol #: 20-1438
Location: University of Colorado Hospital
|
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYMAKER-U02): Substudy 02C
Protocol #: 20-0253
Location: University of Colorado Hospital
|
A PHASE 1 TRIAL OF THE CD123 X CD3 DART? MOLECULE FLOTETUZUMAB (NSC#808294, IND#145986) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
Protocol #: 20-1106
Location: Childrens Hospital Colorado
|
An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies
Protocol #: 20-1380
Location: Childrens Hospital Colorado
|
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and
Clinical Activity Study of Intravenously Administered IO-202 in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients
with Monocytic Differentiation and in Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML) Patients
Protocol #: 20-1388
Locations: Outpatient CTRC; Pathology - SOM; University of Colorado Hospital
|
EA1181 (CompassHER2 pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Protocol #: 20-1318
Locations: Greeley Campus; Harmony Campus; Highlands Ranch Hospital; Lone Tree Medical Center; Medical Center of the Rockies; Poudre Valley Hospital; University of Colorado Hospital
|
ADVL1823: Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Protocol #: 19-2469
Location: Childrens Hospital Colorado
|
A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcome (OLIE)
Protocol #: 20-1210
Location: Childrens Hospital Colorado
|
TENACITY: A Phase 2, Multicenter, Open-label, Single-arm Study of AL101 Monotherapy in Patients with Notch-activated Triple Negative Breast Cancer
Protocol #: 20-1306
Locations: Highlands Ranch Hospital; Lone Tree Medical Center; University of Colorado Hospital
|
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb?23104 in Subjects with Selected Advanced Solid Tumors (DUET-3)
Protocol #: 20-1289
Location: University of Colorado Hospital
|
AN OPEN-LABEL, SAFETY AND TOLERABILITY PHASE 1b TRIAL OF CAN04, A FULLY HUMANIZED ANTI-IL1RAP MONOCLONAL ANTIBODY, IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH SOLID TUMORS PROGRESSING ON PD-1/PD-L1 INHIBITOR-CONTAINING REGIMENS
Protocol #: 20-0605
Locations: Highlands Ranch Hospital; Lone Tree Medical Center; Outpatient CTRC; University of Colorado Hospital
|
A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Protocol #: 20-0884
Locations: Highlands Ranch Hospital; Lone Tree Medical Center; University of Colorado Hospital
|
A Phase 1 study of temozolomide in combination with targeted therapy for NSCLC patients with CNS progression on either osimertinib or lorlatinib
Protocol #: 20-0138
Location: University of Colorado Hospital
|
A Randomized Controlled Trial in Patients Undergoing Immediate Implant-Based Breast Reconstruction Utilizing an Enhanced Recovery Pathway Comparing Outcomes and Patient Satisfaction based on Time of Discharge
Protocol #: 20-1055
Locations: Highlands Ranch Hospital; University of Colorado Hospital
|
A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCINOMA WHO EXPERIENCED RADIOGRAPHIC TUMOR PROGRESSION DURING OR AFTER IMMUNE CHECKPOINT INHIBITOR TREATMENT
Protocol #: 20-0881
Locations: Highlands Ranch Hospital; University of Colorado Hospital
|
Molecular and Genomic Studies of Bone Marrow Failure and Myelodysplastic Syndromes
Protocol #: 16-1438
Location: Childrens Hospital Colorado
|
A Phase 1, First-in-Human, Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients with Advanced Solid Tumors
Protocol #: 20-0727
Location: University of Colorado Hospital
|
Blood based biomarkers for minimal residual disease detection in pediatric sarcomas
Protocol #: 20-0579
Location: Childrens Hospital Colorado
|
Identification of Early Cardiac Injury from Radiation Therapy Using Cardiac MRI
Protocol #: 20-0537
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
S1827, "A Randomized Phase III Trial of MRI Surveillance with or without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer"
Protocol #: 20-0359
Locations: Greeley Campus; Harmony Campus; Highlands Ranch Hospital; Lone Tree Medical Center; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital
|
NRG-GY022: Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Protocol #: 20-0360
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Poudre Valley Hospital; University of Colorado Hospital
|
A Phase 1/2a Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmocokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy
Protocol #: 20-0281
Location: University of Colorado Hospital
|
Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant
Protocol #: 20-0279
Location: Childrens Hospital Colorado
|
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Protocol #: 20-0216
Locations: Highlands Ranch Hospital; University of Colorado Hospital
|
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma
Protocol #: 19-2345
Location: Childrens Hospital Colorado
|
Feasibility, Acceptability, and Effects of Combined Aerobic and Resistance Exercise in Breast Cancer Survivors: A Pilot Study (the CARE study)
This is a 12-week combined aerobic and resistance exercise intervention in breast cancer survivors. Before and after the intervention, women will undergo measures of appetite, energy intake, body composition, and resting metabolic rate....more >
Protocol #: 19-3032
Location: University of Colorado Hospital
|
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions
Protocol #: 20-0124
Location: University of Colorado Hospital
|
An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer
Protocol #: 20-0035
Location: University of Colorado Hospital
|
Phase Ib/II trial of copanlisib in combination with trastuzumab and pertuzumab after
induction treatment of HER2 positive (HER2+ ) metastatic breast cancer (MBC) with PIK3CA mutation or PTEN mutation.
Protocol #: 19-2988
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
First-In-Human Dose-Escalation Study of STP1002 in Patients with Advanced-Stage Solid Tumors
Protocol #: 19-3118
Locations: Outpatient CTRC; University of Colorado Hospital
|
NRG-LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A PHASE III RANDOMIZED STUDY OF CHEMORADIATION VERSUS CHEMORADIATION PLUS ATEZOLIZUMAB
Protocol #: 19-2514
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital
|
A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICOHORT, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL) (TRANSCEND FL)
Protocol #: 19-3011
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
A Pilot Study in the Treatment of Refractory Epstein-Barr Virus (EBV) Infection with Related Donor EBV Cytotoxic T-Lymphocytes in Children, Adolescents and Young Adult Recipients
Protocol #: 19-2695
Location: Childrens Hospital Colorado
|
A Pilot Study in the Treatment of Refractory Cytomegalovirus (CMV) Infections with Related Donor CMV Specific Cytotoxic T-cells (CTLs) in Children, Adolescents and Young Adult Recipients
Protocol #: 19-2694
Location: Childrens Hospital Colorado
|
A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease
Protocol #: 19-2833
Locations: Memorial Hospital Central; University of Colorado Hospital
|
A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T greater than 5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
Protocol #: 19-3018
Location: Rocky Mountain Regional VA Medical Center
|
AN OPEN-LABEL, MULTICENTER, PHASE 1B/2 STUDY OF RP1 IN SOLID ORGAN TRANSPLANT RECIPIENTS WITH ADVANCED CUTANEOUS MALIGNANCIES
Protocol #: 19-2987
Location: University of Colorado Hospital
|
S1826: A PHASE III, RANDOMIZED STUDY OF NIVOLUMAB (OPDIVO) PLUS AVD OR BRENTUXIMAB VEDOTIN (ADCETRIS) PLUS AVD IN PATIENTS (AGE greater than or equal to 12 YEARS) WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA
Protocol #: 19-2950
Location: Childrens Hospital Colorado
|
A PHASE 1/2 STUDY OF TPX-0046, A NOVEL ORAL RET/SRC INHIBITOR IN ADULT SUBJECTS WITH ADVANCED/METASTATIC SOLID TUMORS HARBORING ONCOGENIC RET FUSIONS OR MUTATIONS
Protocol #: 19-2888
Location: University of Colorado Hospital
|
A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects with PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
Protocol #: 19-2818
Location: University of Colorado Hospital
|
A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected population of participants with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) (LEAP-010).
Protocol #: 19-2721
Locations: Highlands Ranch Hospital; University of Colorado Hospital
|
EA3161: A Phase III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC
Protocol #: 19-2554
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital
|
Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia
Protocol #: 19-2405
Location: Childrens Hospital Colorado
|
A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
Protocol #: 19-2640
Location: Rocky Mountain Regional VA Medical Center
|
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
Protocol #: 19-2707
Location: University of Colorado Hospital
|
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Protocol #: 19-2631
Location: Childrens Hospital Colorado
|
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies
Protocol #: 19-2445
Locations: Highlands Ranch Hospital; University of Colorado Hospital
|
ACNS1723, A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)
Protocol #: 19-2475
Location: Childrens Hospital Colorado
|
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Protocol #: 19-2327
Location: University of Colorado Hospital
|
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma
Protocol #: 19-2295
Location: Childrens Hospital Colorado
|
A PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF OQL011 ON VEGFR INHIBITOR-ASSOCIATED HAND-FOOT SKIN REACTION IN CANCER PATIENTS
Protocol #: 19-2242
Locations: Outpatient CTRC; University of Colorado Hospital
|
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity
Protocol #: 19-2270
Location: Childrens Hospital Colorado
|
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (AURIGA)
Protocol #: 19-6114
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Poudre Valley Hospital
|
A PHASE 1/2, MULTI-CENTER, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS,
PHARMACODYNAMICS, AND EFFICACY OF QUIZARTINIB ADMINISTERED IN COMBINATION WITH RE-INDUCTION
CHEMOTHERAPY, AND AS A SINGLE-AGENT CONTINUATION THERAPY, IN PEDIATRIC RELAPSED/REFRACTORY AML SUBJECTS
AGED 1 MONTH TO < 18 YEARS (AND YOUNG ADULTS AGED UP TO 21 YEARS) WITH FLT3-ITD MUTATIONS
Protocol #: 19-2157
Location: Childrens Hospital Colorado
|
S1803: PHASE III STUDY OF DARATUMUMAB/rHuPH20 (NSC- 810307) + LENALIDOMIDE OR LENALIDOMIDE AS POST-AUTOLOGOUS STEM CELL TRANSPLANT MAINTENANCE THERAPY IN PATIENTS WITH MULTIPLE MYELOMA (MM) USING MINIMAL RESIDUAL DISEASE TO DIRECT THERAPY DURATION (DRAMMATIC STUDY)
Protocol #: 19-1589
Location: Rocky Mountain Regional VA Medical Center
|
E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Protocol #: 19-1694
Location: Rocky Mountain Regional VA Medical Center
|
Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer
Protocol #: 19-1977
Location: University of Colorado Hospital
|
The Effects of Acute Resistance Exercise on Energy Balance Regulation among Breast Cancer Survivors
Exercise is important for weight management after treatment for breast cancer. This study aims to assess the effect of exercise on appetite and energy intake after breast cancer treatment. Participants will complete 3-5 study visits at the University of Colorado and receive monetary compen...more >
Protocol #: 19-1974
Locations: Outpatient CTRC; University of Colorado Hospital
|
COG AAML18P1 - Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Protocol #: 19-1839
Location: Childrens Hospital Colorado
|
Prospective Analysis of Circulating Tumor Cells in Patients with Metastatic Prostate Cancer.
Protocol #: 19-1687
Location: University of Colorado Hospital
|
COG AHOD1822 / Merck MK-3475-667:
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)
Protocol #: 19-1481
Location: Childrens Hospital Colorado
|
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination with Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients with HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Protocol #: 19-1727
Location: University of Colorado Hospital
|
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination with Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer Who Have Not Progressed Following First-line Induction of FOLFOX wit Bevacizumab (LYNK-003)
Protocol #: 19-6102
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Poudre Valley Hospital
|
The National Myelodysplastic Syndromes (MDS) Study
Protocol #: 19-1696
Location: Rocky Mountain Regional VA Medical Center
|
COG AALL1731 - A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Protocol #: 19-1634
Location: Childrens Hospital Colorado
|
COG AREN1721 - A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Protocol #: 19-1467
Location: Childrens Hospital Colorado
|
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects with A+AVD."
Protocol #: 19-6510
Locations: Memorial Hospital Central; Memorial Hospital North; Pikes Peak Regional Hospital
|
A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma
Protocol #: 19-1503
Location: University of Colorado Hospital
|
A Phase 1a/b Dose-Finding Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Protocol #: 19-1458
Location: University of Colorado Hospital
|
Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer
Protocol #: 19-6509
Locations: Memorial Hospital Central; Memorial Hospital North; Pikes Peak Regional Hospital
|
A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell Carcinoma.
Protocol #: 19-1337
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
Ublituximab as initial therapy for treatment-naive follicular or marginal zone lymphoma with response-driven addition of umbralisib for suboptimal response.
Protocol #: 18-2128
Location: University of Colorado Hospital
|
GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (GCAR-7213)
Protocol #: 19-0744
Location: University of Colorado Hospital
|
ANBL1821 - A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
Protocol #: 19-1259
Location: Childrens Hospital Colorado
|
Alpha lipoic acid to decrease treatment related pain and side effects during concurrent chemoradiation in HNSCC
Protocol #: 19-1081
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Protocol #: 19-1152
Locations: Greeley Campus; Harmony Campus; Highlands Ranch Hospital; Lone Tree Medical Center; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital
|
S1806: PHASE III RANDOMIZED TRIAL OF CONCURRENT CHEMORADIOTHERAPY WITH OR WITHOUT ATEZOLIZUMAB IN LOCALIZED MUSCLE INVASIVE BLADDER CANCER (Study SWOG/NRG 1806)
Protocol #: 19-1154
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital
|
A Phase I/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors
Protocol #: 19-1277
Location: Childrens Hospital Colorado
|
An Open-Label, Phase II Efficacy Trial of Doxorubicin in Combination with Dual Checkpoint Blockade using Zalifrelimab (AGEN1884) and Balstilimab (AGEN2034) for Advanced or Metastatic Soft Tissue Sarcomas
Protocol #: 19-0554
Location: University of Colorado Hospital
|
A Phase 1/2, Open Label, Dose-Escalation Study of Oral ORIN1001 with and without Chemotherapy in the Treatment of Subjects with Solid Tumors
Protocol #: 19-1118
Locations: Highlands Ranch Hospital; Lone Tree Medical Center; University of Colorado Hospital
|
A151216 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST).A screening trial for A081105, E4512 and EA5142
Protocol #: 18-2625
Location: Rocky Mountain Regional VA Medical Center
|
A Phase 1, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety,
Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of PSB205 in Patients with Relapsed/Refractory Solid Tumors
Protocol #: 19-1069
Locations: Outpatient CTRC; University of Colorado Hospital
|
LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS
Protocol #: 19-0561
Location: University of Colorado Hospital
|
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (SPEARHEAD 1 STUDY)
Protocol #: 19-0967
Location: University of Colorado Hospital
|
A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors
Protocol #: 19-0604
Location: University of Colorado Hospital
|
A Multicenter, Double Blind, Randomized,Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer
Protocol #: 19-6065
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Poudre Valley Hospital
|
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma
Protocol #: 19-0642
Location: University of Colorado Hospital
|
A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
Protocol #: 19-0905
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
A large-scale multicenter phase II study evaluating the protective effect of a tissue selective
estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ.
Protocol #: 19-0632
Locations: Highlands Ranch Hospital; Lone Tree Medical Center; University of Colorado Hospital
|
CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY
Protocol #: 19-0519
Location: University of Colorado Hospital
|
A Multi-Center, Open-Label, phase I/Ib, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients with Advanced Solid Tumors
Protocol #: 19-0539
Location: University of Colorado Hospital
|
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
Protocol #: 19-0493
Locations: Highlands Ranch Hospital; University of Colorado Hospital
|
Phase I trial of ribociclib in combination with everolimus and dexamethasone in children and young adults with relapsed acute lymphoblastic leukemia (DF/HCC Protocol#: 18-328)
Protocol #: 19-0551
Location: Childrens Hospital Colorado
|
A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED MELANOMA
Protocol #: 19-0172
Locations: Outpatient CTRC; University of Colorado Hospital
|
LungMAP: A MASTER PROTOCOL TO EVALUATE BIOMARKER-DRIVEN THERAPIES AND IMMUNOTHERAPIES IN PREVIOUSLY-TREATED NON-SMALL CELL LUNG CANCER (Lung-MAP Screening Study)
Protocol #: 19-0267
Locations: Greeley Campus; Harmony Campus; Highlands Ranch Hospital; Lone Tree Medical Center; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital
|
Phase 1/2 Study to Evaluate The Safety and Pharmacokinetics of Palbociclib (Ibrance?) in Combination With Irinotecan And Temozolomide or in Combination With Topotecan and Cyclophosphamide in Pediatric Patients With Recurrent or Refractory Solid Tumor
Protocol #: 19-0299
Location: Childrens Hospital Colorado
|
CONNECT1702: A Phase Ib Study of PTC596 in children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
Protocol #: 19-0223
Location: Childrens Hospital Colorado
|
A Phase I/Ib Study of Losartan in Combination with Sunitinib in the Treatment of Pediatric and Adult Patients with Relapsed or Refractory Osteosarcoma
Protocol #: 18-2740
Locations: Childrens Healthcare of Atlanta; Childrens Hospital Colorado; Outpatient CTRC; University of Colorado Hospital
|
Creation of a comprehensive database of cancer survivors participating in an exercise program (BFitBwell)
Protocol #: 16-0692
Locations: Anschutz Health and Wellness; UCD Anschutz Health & Wellness Center
|
Randomized phase 2 clinical trial of nab-paclitaxel + durvalumab (MEDI4736) + neoantigen vaccine vs. nab-paclitaxel + durvalumab (MEDI4736) in patients with metastatic triple negative breast cancer
Protocol #: 19-0013
Location: University of Colorado Hospital
|
The MAP TRIAL: PHASE III STUDY OF MUSCADINE PLUS (MPX) IN MEN WITH PROSTATE CANCER: A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF MPX CAPSULES ON RISING PROSTATE-SPECIFIC ANTIGEN LEVELS IN ALANINE/ALANINE SOD2 GENOTYPE MEN FOLLOWING INITIAL THERAPY FOR PROSTATE CANCER
Protocol #: 18-2604
Location: University of Colorado Hospital
|
Pilot Study of Dynamic Contrast Enhanced Computed Tomography (DCE-CT) Imaging for the assessment of radiation therapy outcome for liver cancer patients
Protocol #: 18-2874
Location: University of Colorado Hospital
|
A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER-positive, HER2 negative Advanced Breast Cancer (SERENA-1)
Protocol #: 18-2654
Location: University of Colorado Hospital
|
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors
Protocol #: 18-2520
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
Protocol #: 18-2692
Location: University of Colorado Hospital
|
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Protocol #: 18-2529
Locations: Lone Tree Medical Center; Memorial Hospital Central; Memorial Hospital North; University of Colorado Hospital
|
A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Protocol #: 18-2646
Location: University of Colorado Hospital
|
A Randomized Study of Breast Cancer Patient Engagement with Patient Reported Outcome Measure Survey Results
Protocol #: 18-2562
Locations: Cherry Creek Medical Center; Lone Tree Medical Center; University of Colorado Hospital
|
A Phase 1 First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors
Protocol #: 18-2417
Location: University of Colorado Hospital
|
Predictors of physical activity maintenance in colorectal cancer survivors
Supervised low to moderate intensity aerobic and resistance exercise, twice per week for 60 minutes. Four, 1-hour PA behavior change education/discussion sessions....more >
Protocol #: 18-2436
Locations: Anschutz Health and Wellness; Colorado State University; Harmony Campus; Poudre Valley Hospital; UCD Anschutz Health & Wellness Center
|
Evaluation of Sun Protection Education using the Reveal Imager Photo-aging and the SPA Questionnaire
Protocol #: 17-2424
Locations: University of Colorado Cancer Center; University of Colorado Hospital
|
Prostate oncologic therapy while ensuring neurovascular conservation (POTEN-C): a phase II randomized controlled trial of stereotactic ablative body radiotherapy (SAbR) with or without neurovascular sparing for erectile function preservation in localized prostate cancer
Protocol #: 18-2209
Location: University of Colorado Hospital
|
Phase I/II study of dabrafenib, trametinib, and navitoclax in BRAF mutant melanoma (Phase I and II) and other solid tumors (Phase I only).
Protocol #: 18-2382
Location: University of Colorado Hospital
|
PBTC-049: A Phase I study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS tumors harboring MET aberrations
This is a dose escalation study of savolitinib administered orally once a day to patients with
recurrent, progressive or refractory central nervous system tumors. There are three stages in this study: a dose escalation cohort, PK expansion cohort, and an efficacy expansion cohort. The dos...more >
Protocol #: 18-2432
Location: Childrens Hospital Colorado
|
Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination with Avelumab in MCC Patients who are Anti-PD-1 or Anti-PD-L1 Treatment Naive
Protocol #: 18-2284
Location: University of Colorado Hospital
|
PHASE 1/2 DOSE ESCALATION AND PRELIMINARY EFFICACY OF CD19 DIRECTED CAR T CELLS GENERATED USING THE MILTENYI CLINIMACS PRODIGY SYSTEM (UCD19 CART) IN PEDIATRIC PATIENTS WITH REPLASED AND/OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) AND B-CELL NON-HODGKIN'S LYMPHOMA (B-NHL)
Protocol #: 18-2424
Location: Childrens Hospital Colorado
|
S1802: PHASE III RANDOMIZED TRIAL OF STANDARD SYSTEMIC THERAPY (SST) VERSUS STANDARD SYSTEMIC THERAPY PLUS DEFINITIVE TREATMENT (SURGERY OR RADIATION) OF THE PRIMARY TUMOR IN METASTATIC PROSTATE CANCER
Protocol #: 18-2252
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital
|
A PHASE 1 STUDY OF FOR46 ADMINISTERED EVERY 21 DAYS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Protocol #: 18-2354
Location: University of Colorado Hospital
|
Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR)
Protocol #: 18-2051
Location: University of Colorado Hospital
|
Identifying Predictors of Poor Health-Related Quality-of-Life among Pediatric Hematopoietic Stem Cell Donors
Protocol #: 18-1997
Location: Childrens Hospital Colorado
|
An Open-Label, Multicenter, First-in-Human, Dose-Escalation Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Protocol #: 18-1672
Location: University of Colorado Hospital
|
A multicenter, randomized, double-blinded, placebo-controlled, Phase 3 trial of adjuvant Avelumab (anti-PDL-1 antibody) in Merkel cell carcinoma patients with lymph node metastases
Protocol #: 18-1734
Location: University of Colorado Hospital
|
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
Protocol #: 18-1728
Location: University of Colorado Hospital
|
Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and MK-3475 (Pembrolizumab) Compared to MK-3475 (Pembrolizumab) Alone for Mesothelin-Positive Malignant Pleural Mesothelioma
Protocol #: 18-1654
Location: University of Colorado Hospital
|
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36, for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade
Protocol #: 18-1526
Location: University of Colorado Hospital
|
COG ACCL1633 - The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
Protocol #: 18-1349
Location: Childrens Hospital Colorado
|
An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects 1 and 30 Years of Age with Relapsed/Refractory Precursor B-cell or T-cell Acute Lympholastic Leukemia or Lymphoblastic Lymphoma
Protocol #: 18-0867
Location: Childrens Hospital Colorado
|
AN OPEN-LABEL, MULTICENTER, PHASE Ib/II TRIAL EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH POLATUZUMAB VEDOTIN IN PATIENTS WITH B-CELL NON HODGKIN LYMPHOMA
Protocol #: 18-1439
Locations: Lone Tree Medical Center; Outpatient CTRC; University of Colorado Hospital
|
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Protocol #: 18-6055
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Poudre Valley Hospital
|
Safety and Efficacy of Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients (aged 18-59) with Acute Myeloid Leukemia
Protocol #: 18-0709
Location: University of Colorado Hospital
|
Concomitant Omacetaxine Mepesuccinate and Azacitidine for Patients with Previously Untreated High Grade Myelodysplastic Syndromes
Protocol #: 17-2215
Location: University of Colorado Hospital
|
COG ANBL1531 - A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
Protocol #: 18-0971
Location: Childrens Hospital Colorado
|
A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors
Protocol #: 18-0685
Location: University of Colorado Hospital
|
Effects of Cannabis Use in Cancer Patients: A Feasibility Study
Protocol #: 18-0836
Locations: University of Colorado Hospital; University of Colorado, Boulder
|
PBTC-048: Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma
Protocol #: 18-0498
Location: Childrens Hospital Colorado
|
NANT 2013-01 A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Neuroblastoma with Dinutuximab +/- Lenalidomide. A New Approaches To Neuroblastoma Therapy (NANT) Treatment Protocol
Protocol #: 18-0686
Location: Childrens Hospital Colorado
|
A Phase II, randomized, double-blind, study of the use of Rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer
This is a phase II, randomized, double-blind, trial for the use of Rucaparib as maintenance therapy in metastatic and recurrent endometrial cancer. ...more >
Protocol #: 18-0567
Locations: Fox Chase Cancer Center; University of Colorado Hospital; University of Pennsylvania; University of Pittsburgh Cancer Institute
|
NANT 2017-01: A PHASE I STUDY OF 131I-MIBG WITH DINUTUXIMAB +/- VORINOSTAT FOR RELAPSED/REFRACTORY NEUROBLASTOMA (IND# 137554)
Protocol #: 18-0501
Location: Childrens Hospital Colorado
|
EA1151: Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Participants in this trial will be randomized to receive either 2D or 3D mammograms for the first 5 years of the research study, either ever year or every other year depending on personal risk factors. Information will be collected on breast cancer status for 8 years in total. ...more >
Protocol #: 18-0392
Locations: Highlands Ranch Hospital; Outpatient CTRC; University of Colorado Hospital
|
A PHASE 1 MULTI-CENTER DOSE-ESCALATION STUDY OF THE SAFETY, TOLERABILITY AND EARLY EFFICACY OF TBX-3400 IN PATIENTS WITH STAGE III AND IV MELANOMA RESISTANT OR REFRACTORY TO IMMUNE CHECKPOINT INHIBITORS
Protocol #: 18-0385
Location: University of Colorado Hospital
|
NRG-GI004 Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Protocol #: 18-0018
Locations: Greeley Campus; Harmony Campus; Highlands Ranch Hospital; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital
|
A Novel Lung Function Imaging Modality as a Preoperative Evaluation Tool (LIME)
Protocol #: 17-2216
Locations: Memorial Hospital Central; Memorial Hospital North; University of Colorado Hospital
|
A Phase 1/2 First-in-human Study of BMS-986258 Alone and in Combination with Nivolumab in Advanced Malignant Tumors
Protocol #: 18-0031
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
PBTC-051: Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Protocol #: 17-2394
Location: Childrens Hospital Colorado
|
APEC1621-MASTER, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
Protocol #: 17-2168
Location: Childrens Hospital Colorado
|
COG AALL1631 - International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
Protocol #: 17-2213
Location: Childrens Hospital Colorado
|
A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies
Protocol #: 17-2074
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects with Non-Small Cell Lung Cancer with High PD-L1 Expression
Protocol #: 17-1778
Location: University of Colorado Hospital
|
ACNS1422 - A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Protocol #: 17-1993
Location: Childrens Hospital Colorado
|
ARST1431 - A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Protocol #: 17-1992
Location: Childrens Hospital Colorado
|
A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Protocol #: 17-2036
Locations: Greeley Campus; Highlands Ranch Hospital; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital
|
A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Protocol #: 17-1808
Location: University of Colorado Hospital
|
A Safety and Preliminary Efficacy trial of Pembrolizumab (MK-3475) in children with recurrent, progressive or refractory diffuse intrinsic pontine glioma (DIPG), non-brainstem high-grade gliomas (NB-HGG), ependymoma, medulloblastoma or hypermutated brain tumors
Protocol #: 17-1991
Location: Childrens Hospital Colorado
|
A non-randomized, open-label, multi-center, Phase I/II study of PI3K inhibitor copanlisib in pediatric patients with relapsed/refractory solid tumors or lymphoma (BAY 80-6946 /19176)
Protocol #: 17-1495
Location: Childrens Hospital Colorado
|
A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Protocol #: UCH13-1230
Locations: Memorial Hospital Central; Memorial Hospital North; Pikes Peak Regional Hospital
|
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Protocol #: 17-1410
Location: University of Colorado Hospital
|
Anal Cancer/HSIL Outcomes Research (ANCHOR) Study
Protocol #: 15-1466
Locations: Denver Health and Hospital Authority; University of Colorado Hospital
|
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Protocol #: 17-1043
Location: Childrens Hospital Colorado
|
E7080-A001-216: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Protocol #: 17-1165
Location: Childrens Hospital Colorado
|
A Phase I Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies (M13-833)
Protocol #: 17-0564
Location: Childrens Hospital Colorado
|
AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#TBD) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Protocol #: 17-1086
Location: Childrens Hospital Colorado
|
A Phase IA/IB Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Tumors
Protocol #: 17-0991
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies
Protocol #: 17-0500
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
NANT 2015-02: PHASE 1 STUDY OF LORLATINIB (PF-06463922), AN ORAL SMALL MOLECULE INHIBITOR OF ALK/ROS1, FOR PATIENTS WITH ALK-DRIVEN RELAPSED OR REFRACTORY NEUROBLASTOMA
Protocol #: 17-0511
Location: Childrens Hospital Colorado
|
Phase 1 trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers
Protocol #: 17-0512
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
NRG-GU002, PHASE II-III TRIAL OF ADJUVANT RADIOTHERAPY AND ANDROGEN DEPRIVATION FOLLOWING RADICAL PROSTATECTOMY WITH OR WITHOUT ADJUVANT DOCETAXEL
Protocol #: 17-0266
Locations: Broomfield Hospital; Grandview Hospital; Greeley Campus; Harmony Campus; Highlands Ranch Hospital; Lone Tree Medical Center; Long's Peak Hospital; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Pikes Peak Regional Hospital; Poudre Valley Hospital; University of Colorado Hospital
|
CRIZOTINIB (XALKORI) EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADULT OR PEDIATRIC PATIENTS WITH SOLID OR HEMATOLOGIC MALIGNANCIES THAT HARBOR A CRIZOTINIB-SENSITIVE MOLECULAR ALTERATION BUT WHO ARE UNABLE TO SWALLOW CRIZOTINIB CAPSULES
Protocol #: 16-2544
Location: Childrens Hospital Colorado
|
A Phase 1/2, Dose Escalation Study of Intravenous TK216 in Patients with Relapsed or Refractory Ewing Sarcoma
Protocol #: 16-2158
Location: Childrens Hospital Colorado
|
Is disruption of the human gut microbial environment associated with cognitive impairment following chemotherapy for breast cancer?
Protocol #: 16-2138
Location: University of Colorado Hospital
|
ADVL1414: A PHASE 1 STUDY OF SELINEXOR (KPT-330, IND #125052), A SELECTIVE XPO1 INHIBITOR, IN RECURRENT AND REFRACTORY PEDIATRIC SOLID TUMORS, INCLUDING CNS TUMORS
Protocol #: 15-1936
Location: Childrens Hospital Colorado
|
NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS: CLINICAL AND MOLECULAR RISK-TAILORED INTENSIVE AND COMPRESSED INDUCTION CHEMOTHERAPY FOLLOWED BY CONSOLIDATION WITH EITHER SINGLE CYCLE (LOW RISK PATIENTS) OR RANDOMIZATION (HIGH RISK PATIENTS) TO EITHER SINGLE-CYCLE or TO THREE TANDEM CYCLES OF MARROW-ABLATIVE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC PROGENITOR
CELL RESCUE
Protocol #: 16-1804
Location: Childrens Hospital Colorado
|
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway Mutant Acute Lymphoblastic Leukemia
Protocol #: 16-1970
Location: Childrens Hospital Colorado
|
PHASE 2 STUDY OF ALISERTIB AS A SINGLE AGENT IN RECURRENT OR PROGRESSIVE CENTRAL NERVOUS SYSTEM (CNS) ATYPICAL TERATOID RHABDOID TUMORS (AT/RT) AND EXTRA-CNS MALIGNANT RHABDOID TUMORS (MRT) AND IN COMBINATION THERAPY IN NEWLY DIAGNOSED AT/RT (SJATRT)
Protocol #: 15-1302
Location: Childrens Hospital Colorado
|
AR22.001 Vigilant ObservatIon of G1IadeL Wafer ImplaNT (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Effectiveness of Gliadel Wafer (Carmustine Implant) Used in Usual Medical Practice
Protocol #: 15-2153
Location: University of Colorado Hospital
|
A Phase 2 Study of Grape Seed Extract (GSE) Product in Asymptomatic or Minimally Symptomatic Non-Metastatic Prostate Cancer Patients with Rising PSA
Protocol #: 16-0607
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Poudre Valley Hospital; University of Colorado Hospital
|
051/02 A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)
Protocol #: 16-0064
Location: Childrens Hospital Colorado
|
A Phase 1/2, Open-Label, Dose-Escalation and Expansion study of Entrectinib (RXDX-101) in Pediatrics with Locally Advanced or Metastatic Solid or Primary CNS Tumors and/or Who Have No Satisfactory Treatment Options
Protocol #: 16-0749
Location: Childrens Hospital Colorado
|
A Phase II, Open Label, Two-Arm Study of Therapeutic Iobenguane (131I) as Single Agent or in Combination with Vorinostat For Recurrent or Progressive High-Risk Neuroblastoma Subjects (Optimum Trial)
Protocol #: 16-0742
Location: Childrens Hospital Colorado
|
AAML1531 Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Protocol #: 16-0709
Location: Childrens Hospital Colorado
|
Multicenter Cohort Study To Evaluate Outcomes after Receipt of Targeted Therapy Matched to an Individualized Cancer Therapy (iCat) Recommendations in Children and Young Adults with Solid Tumors:
The iCat2, GAIN Consortium Study
Protocol #: 16-0216
Location: Childrens Hospital Colorado
|
15-2316 Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Targeted Therapy in patients with EGFR, ALK, ROS1 or BRAF mutations
The primary objective is to 1- Identify differences between pretreatment and early treatment tumor samples in patients whose tumors contain activating mutations and who will be treated with targeted agents as first-line therapy.
a. Measurement of gene expression signatures of pre-and ear...more >
Protocol #: 15-2316
Locations: Lone Tree Medical Center; University of Colorado Hospital
|
14-1076 Molecular Biology and Phase I Study of GM-CSF and Intrathecal Trastuzumab in Children with Recurrent Ependymoma
Protocol #: 14-1076
Location: Childrens Hospital Colorado
|
EAY131 Molecular Analysis for Therapy Choice (MATCH)
Protocol #: 15-1111
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital
|
Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer (ORIEN)
Protocol #: 15-1110
Locations: Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital
|
E4512 A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Protocol #: 14-1915
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital
|
PT-112-101 A Phase I, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-122 Injection in Subjects with Advanced Solid Tumors
Protocol #: 14-0151
Locations: Outpatient CTRC; University of Colorado Hospital
|